• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by SomaLogic Inc. (Amendment)

    1/29/24 5:25:49 PM ET
    $SLGC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $SLGC alert in real time by email
    SC 13G/A 1 us83444k1051_012924.txt us83444k1051_012924.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) SomaLogic, Inc. -------------------------------------------------------- (Name of Issuer) Class A Common Stock -------------------------------------------------------- (Title of Class of Securities) 83444K105 -------------------------------------------------------- (CUSIP Number) December 31, 2023 -------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 83444K105 (1)Names of reporting persons. BlackRock, Inc. (2) Check the appropriate box if a member of a group (a) [ ] (b) [X] (3) SEC use only (4) Citizenship or place of organization Delaware Number of shares beneficially owned by each reporting person with: (5) Sole voting power 11201163 (6) Shared voting power 0 (7) Sole dispositive power 11548774 (8) Shared dispositive power 0 (9) Aggregate amount beneficially owned by each reporting person 11548774 (10) Check if the aggregate amount in Row (9) excludes certain shares (11) Percent of class represented by amount in Row 9 6.1% (12) Type of reporting person HC Item 1. Item 1(a) Name of issuer: ----------------------------------------------------------------------- SomaLogic, Inc. Item 1(b) Address of issuer's principal executive offices: ----------------------------------------------------------------------- 2945 WILDERNESS PLACE BOULDER CO 80301 Item 2. 2(a) Name of person filing: ---------------------------------------------------------------------- BlackRock, Inc. 2(b) Address or principal business office or, if none, residence: ----------------------------------------------------------------------- BlackRock, Inc. 50 Hudson Yards New York, NY 10001 2(c) Citizenship: -------------------------------------------------------------------- See Item 4 of Cover Page 2(d) Title of class of securities: ------------------------------------------------------------------- Class A Common Stock 2(e) CUSIP No.: See Cover Page Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a: [ ] Broker or dealer registered under Section 15 of the Act; [ ] Bank as defined in Section 3(a)(6) of the Act; [ ] Insurance company as defined in Section 3(a)(19) of the Act; [ ] Investment company registered under Section 8 of the Investment Company Act of 1940; [ ] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); [ ] An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); [X] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G); [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940; [ ] A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J); [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: Item 4. Ownership Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. Amount beneficially owned: 11548774 Percent of class 6.1% Number of shares as to which such person has: Sole power to vote or to direct the vote 11201163 Shared power to vote or to direct the vote 0 Sole power to dispose or to direct the disposition of 11548774 Shared power to dispose or to direct the disposition of 0 Item 5. Ownership of 5 Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [ ]. Item 6. Ownership of More than 5 Percent on Behalf of Another Person If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of SomaLogic, Inc.. No one person's interest in the common stock of SomaLogic, Inc. is more than five percent of the total outstanding common shares. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. See Exhibit A Item 8. Identification and Classification of Members of the Group If a group has filed this schedule pursuant to Rule 13d-1(b)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identity of each member of the group. Item 9. Notice of Dissolution of Group Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5. Item 10. Certifications By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: January 29, 2024 BlackRock, Inc. Signature: Spencer Fleming ------------------------------------------- Name/Title Attorney-In-Fact The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature. Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001). Exhibit A Subsidiary Aperio Group, LLC BlackRock Advisors, LLC BlackRock Investment Management (UK) Limited BlackRock Asset Management Canada Limited BlackRock Fund Advisors BlackRock Asset Management Ireland Limited BlackRock Institutional Trust Company, National Association BlackRock Financial Management, Inc. BlackRock Fund Managers Ltd BlackRock Japan Co., Ltd. BlackRock Asset Management Schweiz AG BlackRock Investment Management, LLC *Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Exhibit B POWER OF ATTORNEY The undersigned, BlackRock, Inc., a corporation duly organized under the laws of the State of Delaware, United States (the "Company"), does hereby make, constitute and appoint each of Eric Andruczyk, Richard Cundiff, R. Andrew Dickson, III, Spencer Fleming, Daniel Goldmintz, Laura Hildner, Elizabeth Kogut, David Maryles, Christopher Meade, Una Neary, Charles Park, Daniel Riemer, David Rothenberg and Brenda Schulz, acting severally, as its true and lawful attorneys-in-fact, for the purpose of, from time to time, executing, in its name and on its behalf and on behalf of its direct and indirect subsidiaries, any and all documents, certificates, instruments, statements, filings, agreements and amendments (collectively, "documents") determined by such person to be necessary or appropriate to comply with ownership or control-person reporting requirements imposed by any United States or non-United States governmental or regulatory authority, including, without limitation, Schedules 13D and 13G and Forms 3, 4, 5, 13F and 13H and any amendments to any of the foregoing as may be required to be filed with the Securities and Exchange Commission, and delivering, furnishing or filing any such documents with the appropriate governmental or regulatory authority or other person, and giving and granting to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully and to all intents and purposes as the Company and/or its direct and indirect subsidiaries, as applicable, might or could do if personally present by one of its authorized signatories, hereby ratifying and confirming all that said attorney-in-fact shall lawfully do or cause to be done by virtue hereof. Any such determination by an attorney-in-fact named herein shall be conclusively evidenced by such person's execution, delivery, furnishing or filing of the applicable document. This power of attorney shall expressly revoke the power of attorney dated 2nd day of January, 2019 in respect of the subject matter hereof, shall be valid from the date hereof and shall remain in full force and effect until either revoked in writing by the Company, or, in respect of any attorney-in-fact named herein, until such person ceases to be an employee of the Company or one of its affiliates. IN WITNESS WHEREOF, the undersigned has caused this power of attorney to be executed as of this 30th day of April, 2023. BlackRock, Inc. By: /s/ R. Andrew Dickson, III Name: R. Andrew Dickson, III Title: Corporate Secretary
    Get the next $SLGC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SLGC

    DatePrice TargetRatingAnalyst
    10/5/2023$3.50 → $2.29Buy → Hold
    Jefferies
    9/25/2023$5.00 → $2.50Buy → Hold
    Canaccord Genuity
    2/1/2022$12.00Buy
    Stifel
    12/14/2021$19.00Buy
    Canaccord Genuity
    12/10/2021$16.00Buy
    Jefferies
    11/23/2021$18.00Outperform
    Cowen & Co.
    More analyst ratings

    $SLGC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • OncoHost Selected to Present in Oral Minisymposium at American Association of Cancer Research (AACR) Annual Meeting 2024

      Data to showcase PROphet® platform's machine learning models for predicting therapeutic benefit and immune-related adverse events in non-small cell lung cancer patients treated with immunotherapy BINYAMINA, Israel and CARY, N.C., March 5, 2024 /PRNewswire/ -- OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, today announced it will be presenting new results at the American Association for Cancer Research (AACR) Annual Meeting taking place in San Diego, California from April 5-10, 2024. The oral presentation will feature insights from the company's PROPHETIC trial, to be delivered by Prof. Jarushka Naidoo, consultant medical oncologi

      3/5/24 4:35:00 PM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Standard BioTools Stockholders Approve Merger with SomaLogic

      SOUTH SAN FRANCISCO, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health, today announced that its stockholders voted to approve all proposals required to be approved in connection with the pending merger with SomaLogic (NASDAQ:SLGC) at its Special Meeting of Stockholders. "We are pleased with the outcome of today's Special Meeting and thank our stockholders for their support for this merger," said Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools. "Together with SomaLogic, we will have an expanded platform to better serve our customers and we be

      1/4/24 10:23:06 PM ET
      $LAB
      $SLGC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SomaLogic Stockholders Vote to Approve Standard BioTools Transaction at Special Meeting

      Stockholder Approval Represents Key Milestone Toward Completion of Standard BioTools Transaction Combination Will Create a Diversified Leader in Life Sciences Tools BOULDER, Colo., Jan. 4, 2024 /PRNewswire/ -- SomaLogic, Inc. (NASDAQ:SLGC) ("the Company"), a leader in proteomics technology, today announced that, based on the preliminary vote count provided by its proxy solicitors following the Company's Special Meeting of Stockholders (the "Special Meeting") held earlier today, SomaLogic stockholders voted to approve the transaction with Standard BioTools Inc. (NASDAQ:LAB) ("Standard BioTools"). The SomaLogic Board of Directors issued the following statement: We are grateful for the suppor

      1/4/24 9:44:00 PM ET
      $LAB
      $SLGC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $SLGC
    SEC Filings

    See more
    • SEC Form 15-12G filed by SomaLogic Inc.

      15-12G - SomaLogic, Inc. (0001837412) (Filer)

      1/16/24 8:00:29 AM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form EFFECT filed by SomaLogic Inc.

      EFFECT - SomaLogic, Inc. (0001837412) (Filer)

      1/12/24 12:15:06 AM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form EFFECT filed by SomaLogic Inc.

      EFFECT - SomaLogic, Inc. (0001837412) (Filer)

      1/12/24 12:15:08 AM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $SLGC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Taich Adam returned 48,425 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - SomaLogic, Inc. (0001837412) (Issuer)

      1/9/24 9:54:27 PM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4 filed by Ryan Jason

      4 - SomaLogic, Inc. (0001837412) (Issuer)

      1/9/24 9:53:22 PM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Roelke Alison Marie returned 17,143 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - SomaLogic, Inc. (0001837412) (Issuer)

      1/9/24 9:52:15 PM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $SLGC
    Financials

    Live finance-specific insights

    See more
    • SomaLogic Board Reiterates Value-Maximizing Transaction with Standard BioTools is in Best Interests of All Stockholders

      Continues to Recommend Stockholders Vote "FOR" Pending Merger ISS has Dismissed Madryn's Misleading Claims and Reaffirms that Stockholders Vote "FOR" the Merger BOULDER, Colo., Dec. 29, 2023 /PRNewswire/ -- SomaLogic, Inc. (NASDAQ:SLGC) ("the Company"), a leader in proteomics technology, today sent the following open letter to stockholders reiterating the Board's belief that the proposed transaction between SomaLogic and Standard BioTools is in the best interest of all stockholders. The full text of the letter is as follows: Dear Fellow Stockholders, We firmly believe that the value-maximizing transaction with Standard BioTools is the best path forward for SomaLogic and all of its stockhold

      12/29/23 8:42:00 AM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • ISS Recommends SomaLogic Stockholders Vote "FOR" Proposed Merger with Standard BioTools

      BOULDER, Colo., Dec. 22, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today announced that Institutional Shareholder Services ("ISS") has recommended that SomaLogic stockholders vote "FOR" the pending merger with Standard BioTools at the company's Special Meeting of Stockholders to be held on January 4, 2024. In its "FOR" recommendation to SomaLogic stockholders, ISS noted1: The strategic rationale of combining two sub-scale companies in order to slow down cash burn and accelerate the path to profitability appears reasonable, particularly given the apparent overlap in the two companies' offerings and the estimated synergies in this transaction.…the all-sto

      12/22/23 6:47:52 PM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SomaLogic Issues Letter to Stockholders Reiterating Recommendation for Value Maximizing Merger with Standard BioTools

      Combination Builds Scale and Accelerates Path to Profitability, Unlocking Significant Potential Value for SomaLogic Stockholders Madryn's Concerns are Not Based on Facts, and Madryn Selectively Ignores Risks in a Standalone Strategy and Potential Benefits of the Merger Urges Stockholders to Vote "FOR" Merger Ahead of Special Meeting of Stockholders on January 4, 2024 BOULDER, Colo., Dec. 21, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc. (NASDAQ:SLGC) today issued an open letter to stockholders highlighting the value maximizing merger entered into with Standard BioTools (NASDAQ:LAB) on October 4, 2023. The Company also filed an investor presentation, which can be found on th

      12/21/23 8:00:00 AM ET
      $LAB
      $SLGC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $SLGC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by SomaLogic Inc. (Amendment)

      SC 13G/A - SomaLogic, Inc. (0001837412) (Subject)

      1/29/24 5:25:49 PM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G/A filed by SomaLogic Inc. (Amendment)

      SC 13G/A - SomaLogic, Inc. (0001837412) (Subject)

      1/29/24 4:00:59 PM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13D/A filed by SomaLogic Inc. (Amendment)

      SC 13D/A - SomaLogic, Inc. (0001837412) (Subject)

      1/9/24 5:16:22 PM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $SLGC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • SomaLogic downgraded by Jefferies with a new price target

      Jefferies downgraded SomaLogic from Buy to Hold and set a new price target of $2.30 from $3.50 previously

      10/5/23 7:49:23 AM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SomaLogic downgraded by Canaccord Genuity with a new price target

      Canaccord Genuity downgraded SomaLogic from Buy to Hold and set a new price target of $2.50 from $5.00 previously

      9/25/23 9:02:13 AM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Stifel initiated coverage on SomaLogic with a new price target

      Stifel initiated coverage of SomaLogic with a rating of Buy and set a new price target of $12.00

      2/1/22 6:15:39 AM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $SLGC
    Leadership Updates

    Live Leadership Updates

    See more
    • Madryn Asset Management, a Top Shareholder of SomaLogic, Issues Letter Regarding Opposition to the Company's Proposed Merger with Standard BioTools

      Files Preliminary Proxy Statement to Solicit Shareholders to Oppose the Merger Intends to Vote AGAINST the Conflict-Plagued and Excessively Dilutive Transaction, Which Stands to Unduly Benefit Certain Investors and Standard BioTools at the Expense of SomaLogic's Shareholders Notes the Current Premium for SomaLogic Shareholders, Based on the Deal's Exchange Ratio and Standard BioTools' Trading Price, is Only ~4.3% Underscores That SomaLogic Has Superior Alternatives to a Flawed Combination, Including a Standalone Path Leveraging its Considerable Cash Position and Strong Balance Sheet Madryn Asset Management, LP (collectively with its affiliates, "Madryn"), a holder of approximately 4

      12/12/23 5:31:00 PM ET
      $EXAS
      $ILMN
      $LAB
      $ME
      Medical Specialities
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SomaLogic Announces Chief Financial Officer Transition

      Appoints Eliot M. Lurier, CPA, as Interim Chief Financial Officer Reaffirms 2023 Financial Guidance BOULDER, Colo., June 06, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc. (NASDAQ:SLGC), a leader in proteomics technology, today announced a Chief Financial Officer transition. Eliot M. Lurier, CPA, is joining the company as Interim CFO while the Company conducts a search for a permanent CFO. Shaun Blakeman has left the company, effective June 5, 2023. Mr. Lurier has over 35 years of experience in financial and leadership positions across the life science industry. He will report directly to the Interim CEO and immediately embed within the finance organization to ensure a seamless transiti

      6/6/23 4:05:00 PM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SomaLogic Announces the Appointment of Biotech Veteran Troy Cox as Executive Chairman of the Board of Directors

      BOULDER, Colo. and SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ:SLGC), a leader in AI data-driven proteomics technology, today announced the appointment of current board member and biotech veteran Troy Cox as Executive Chair to the company's Board of Directors. The current Chair, Chuck Lillis, will remain on the board. Changes are effective as of today, October 17, 2022. Mr. Cox brings over thirty years of experience in the life sciences and biopharmaceuticals industry to his expanded position as Executive Chair of the Board. Mr. Cox was the President and CEO of Foundation Medicine from early 2017 through the acquisition by Roche, valuing Foundation Medicine at $5.3 bill

      10/17/22 4:30:00 PM ET
      $SLGC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care